Fred brings to IGM extensive operational, financial and management experience, including his experience in public and private equity financing, business development and corporate partnerships. Fred has been the chairman of eight life sciences companies and was a founder and managing partner of Charter Life Sciences, a venture capital firm that specializes in life sciences investments.
Fred was previously the chief executive officer and then chairman of Heska (HSKA). During his tenure at Heska, Fred completed Heska’s initial public offering and follow-on public offering, as well as multiple corporate partnerships and acquisitions. During this time, Heska obtained its first FDA approval, launched its first products, created its sales and marketing effort and grew its revenue to approximately $40 million.
Fred was also the chief executive officer of Mingly Capital Corporation, which was focused on developing cross-border (China/U.S.) opportunities in life sciences and information technology. He was also an executive director of the Mingly Corporation Limited (listed on the Hong Kong Stock Exchange), and previously he was a senior vice president of C.M. Capital, a diversified asset management company.
Fred began his professional career as an attorney, primarily representing technology companies and venture capitalists. He was a partner with Pillsbury, Madison & Sutro (now Pillsbury), and he founded the firm of General Counsel Associates (now GCA Law Partners). Fred holds a JD from the University of California, Berkeley School of Law and a BA from the University of Michigan.
Bruce brings to IGM more than thirty-five years of research, development and management experience in large and small biotechnology companies, including his extensive experience in many phases of early stage biotech drug discovery and development. This experience spans target selection and discovery, in vitro biochemistry, in vivo efficacy models and all other aspects of the pre-clinical development of antibodies and proteins as therapeutic agents.
During his 16 years at Genentech, Bruce contributed to the development of five marketed products (Factor VIII, Activase, TNKase, Avastin and Lucentis). His many accomplishments include leadership of the VEGF/anti-VEGF project team which selected antibodies for anti-tumor and ocular disease treatments and the development of long half-life, more potent forms of tPA resulting in the improved thrombolytic, TNKase. Bruce also made key contributions to the effort which isolated the anti-hemophilic factor which allowed the cloning and production of recombinant human Factor VIII.
At Millennium Biotherapeutics, Bruce was director of pharmacology, where he built a team of preclinical scientists working on biotherapies based on genomic research at Millennium Pharmaceuticals.
As vice president of preclinical development at Abgenix, Bruce led the preclinical development efforts of more than 20 therapeutic antibody candidates, resulting in the filing of two INDs and an approved BLA for Vectabix, an anti-EGFr antibody.
As chief scientific officer at Trellis Biosciences, Bruce led a team that isolated human anti-respiratory syncyctial virus antibodies from patients with RSV, and he helped validate and license those antibodies to Medimmune, now part of AstraZeneca.
Bruce received his PhD in biochemistry and pharmacology from Tufts University School of Medicine and his BS in Chemistry from Washington University in St Louis. He is a co-inventor on more than 35 U.S. patents and patent applications, and he has co-authored more than 55 scientific articles.
Dan brings to IGM his extensive clinical drug development experience from pre-IND to Phase IV as well as his reputation as one of the world’s leading experts in cancer immunotherapy.
Dan spent over 12 years at Genentech from 2006-2018, where he ultimately served as Vice President, Global Head of Cancer Immunotherapy. During his time at Genentech, he contributed to over 20 cancer immunotherapy and anti-angiogenic new molecular agents (including anti-PD-L1, anti-EGFL7, anti-NRP1, anti-alpha5beta1) as clinical lead or diagnostic lead. Dan was the atezolizumab (anti-PD-L1) clinical lead from the time the program was in research through filing and approvals in multiple indications worldwide. At Genentech, his roles expanded from clinical lead, development lead, early development cancer immunotherapy group lead, global development lead, to cancer immunotherapy franchise head. He was also a founder and ultimately co-chair of the Genentech/Roche cross organizational cancer immunotherapy committee. During his time at Genentech, Dan built an extensive team dedicated to the development of cancer immunotherapy drugs, and he was instrumental in the development of a number of innovative initiatives, including the MORPHEUS early combinations platform, immune-modified RECIST and the imCORE global cooperative group network for research and development collaboration.
In addition to his work within Genentech/Roche, Dan has also played an important role in the broader cancer immunotherapy research community. He is currently co-chair of the Cancer Immunotherapy Committee (CIC, an arm of the Cancer Research Institute) and was recently elected a member of the Board of Directors for the Society for Immunotherapy of Cancer (SITC). He also presented at the U.S. Congressional Hearing on Cancer Immunotherapy in 2017.
Dan received his BS degree in Biology from the Massachusetts Institute of Technology and an MD and a PhD from the University of Southern California (Microbiology & Immunology). He completed his Residency in Internal Medicine, a Fellowship in Medical Oncology and a Fellowship in Immunology at Stanford. Dan also ran the metastatic melanoma clinic at the Stanford Cancer Center, where he studied human immune responses to cancer vaccination and cytokine administration. During that period, Dan also developed a novel MHC cellular microarray along with his co-inventors. Dan continued to care for melanoma patients at Stanford until 2016.
Dan is a co-inventor on multiple patents and has authored multiple scientific articles. He continues to serve as a reviewer for the journals Nature, Immunity, Clinical Cancer Research, and he gave the Keynote Presentation at the AACR NCI EORTC Annual Meeting in 2014. He has continued to publish with academic and industry collaborators, including the often referenced Chen and Mellman manuscripts, “Elements of cancer immunity and the cancer-immune set point” and “Oncology meets Immunology: the Cancer-Immunity Cycle.”
Ramesh brings to IGM a broad range of research and development skills and experience, including extensive experience in protein engineering, expression and purification, cell line development and bio-analytic testing.
At Sutro Biopharma, Ramesh led the team that developed a high-throughput platform for cell-free protein expression of IgGs and site-specifically labeled ADCs.
While at Catalyst Biosciences, Ramesh built and led a team that used rational design, combined with semi-automated phage-display, to engineer and screen for proteases with radically altered substrate specificity, catalytic activity and plasma inhibitor resistance (Alterase™ technology). One of these molecules, a FVIIa variant (CB813d/Marzeptacog alfa), is currently in Phase II clinical trials for Hemophilia A.
At Cytokinetics, Ramesh contributed to the discovery of small molecule modulators of cytoskeletal proteins, for cardiovascular and oncology indications. Two of these, Omecamtiv Mecabril and Tirasemtiv, are currently in clinical trials for congestive heart failure (CHF) and Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig’s disease).
Ramesh received a PhD in Bioorganic Chemistry from California Institute of Technology and an MSc in Organic Chemistry from the Indian Institute of Technology, Mumbai. He is a co-author on numerous scientific publications and a co-inventor on 11 U.S. patents and patent applications.
Steve brings to IGM more than 30 years of academic and biotech industry experience, including extensive experience in protein biochemistry, pharmacology and toxicology and the evaluation and development of antibodies, antibody fragments, enzymes, conjugates and proteins.
Steve’s experience includes 17 years at Xoma, a biotechnology company specializing in the development of antibodies and recombinant proteins for use in inflammation, cancer, autoimmune disorders and infectious disease. As its vice president of preclinical research and scientific and product development, he managed a large preclinical research group and served as an interface between his group and Xoma’s research, development, manufacturing, clinical, regulatory, finance, patent and legal teams.
Prior to joining Xoma, Steve was an Assistant Professor of Microbiology and Molecular Genetics at Harvard Medical School and a Postdoctoral Fellow and Adjunct Lecturer in Microbiology at the University of California, Los Angeles.
Steve received a PhD in Microbiology from the University of California, Los Angeles, and a BA in biology from the University of California, San Diego. He is a co-inventor on more than 40 U.S. patents and patent applications and a co-author of more than 60 scientific articles.
Wayne brings to IGM more than 25 years of research and development experience in academia and industry. He is a pioneer in the field of cancer immunotherapy, and he has led both basic science groups and clinical development teams from pre-IND to Phase IV in both biotech and pharma.
Prior to coming to IGM, Wayne was the clinical lead for the pivotal Zuma-5 program of CAR-T therapy for Follicular Lymphoma at Kite/Gilead. Previously he served as Chief Medical Officer at Bavarian Nordic Immunotherapeutics and Etubics, developing viral vaccine approaches to activate anti-cancer immunity. In between those roles, he was clinical lead on multiple studies of Idelalisib (PI3-Kinase inhibitor) in Non-Hodgkin Lymphoma, and contributed to the FDA approval of Zydelig® at Gilead Sciences and publication of the work in The New England Journal of Medicine. He started in industry working on antigen presenting cell vaccines at Dendreon and TLR agonists at Hemispherx Biopharma.
Prior to joining industry, Wayne was a faculty member in Hematology, Oncology and Transplantation at the University of Minnesota. His work led to publications and patents related to methods to purify and culture adult blood and cord blood derived T regulatory cells. Wayne did post-doctoral research with Ed Engleman at Stanford University, where he identified and characterized human OX40 and OX40Ligand and was a co-inventor and author on some of the seminal patents and publications in this area.
Wayne received an MD from Washington University, an MS in Biology from Stanford University, and a BA in Biochemistry and Molecular Biology at the University of California, Santa Barbara. He completed his internal medicine residency and Clinical Immunology, Hematology and Bone Marrow Transplantation Fellowships at Stanford University.
Marvin brings to IGM more than 25 years of biotech industry experience, including extensive experience in protein expression, cell line development, upstream and downstream process development and the manufacturing of biologic drugs.
Most recently, Marvin was in charge of manufacturing at MabVax Therapeutics, where he contributed to the successful clinical manufacture, IND filing and clinical trial initiation of three oncology antibody products.
Marvin’s prior experience also includes 15 years at Bristol-Myers Squibb, Eli Lilly, Celgene and Shire. During this time, he contributed to the development of processes for numerous therapeutics, including Orencia® for adult rheumatoid arthritis, and the commercial manufacturing of Dermagraft® for diabetic foot ulcers.
While heading up biologics manufacturing at Althea Technologies (now Ajinomoto Althea), Marvin helped build a GMP manufacturing facility and established strong process development and formulation groups.
Marvin received a PhD in Chemical Engineering from Purdue University and a BS in Chemical Engineering from the University of Colorado, Boulder. He was also a Postdoctoral fellow in the BioProcess Technology Institute at the University of Minnesota.
Angus brings to IGM over 25 years of academic and biotech industry experience researching, discovering and developing large and small molecule therapeutics in hematology and oncology indications.
Prior to joining IGM, Angus was the senior director of Oncology of Northern Biologics, Toronto where he led the preclinical development of the oncology antibody portfolio, culminating in the successful IND approval of a novel immuno-oncology antibody.
As a scientific director of Oncology Research at Amgen, Angus led preclinical teams to develop antibody-based and small molecule therapeutics in oncology and hematology indications. He advanced programs from target identification/validation, hit-to-lead identification and characterization though IND filings, with continued support of drug candidate development through clinical trials.
Angus also led BiTE® immuno-oncology programs for the treatment of AML and MDS, currently in clinical trials, as well as supporting the BiTE® platform for multiple solid tumor indications. During his tenure, Angus also served as Amgen’s scientific expert for Aranesp®, Epogen® and Nplate®, providing guidance and support to clinical, regulatory and marketing leads.
Prior to joining Amgen, Angus held faculty and postdoctoral positions at UT Southwestern Medical Center in Texas; the University of Cambridge in the United Kingdom and the University of California, San Diego in California where he researched regulators of hematopoiesis and hematological malignancy as well as polycystic kidney disease and stem cell directed gene therapy.
Angus obtained his PhD in Hematology at the National Institute for Medical Research/University College London, UK and a BSc Hons in Molecular Biology from the University of Edinburgh, UK. During his scientific career, Angus has co-authored over 40 scientific articles.